Evusheld

Department of Health and Social Care written question – answered on 28th November 2022.

Alert me about debates like this

Photo of Baroness Whitaker Baroness Whitaker Labour

To ask His Majesty's Government when they expect a decision to be made as to the suitability of prescribing Evusheld on the NHS.

Photo of Baroness Whitaker Baroness Whitaker Labour

To ask His Majesty's Government what factors they are taking into account as they reach a decision on the suitability of prescribing Evusheld on the NHS.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

The Government has decided not to procure Evusheld at this time for prevention through emergency routes. This is a decision based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group, which considered all available evidence for whether treatments are likely to be effective at preventing symptomatic infection, hospitalisation or mortality from COVID-19. The groups concluded that there is currently insufficient evidence of benefit to recommend deployment at this time.

Evusheld has now been referred to the National Institute for Health and Care Excellence (NICE) for evaluation. NICE’s appraisal process will consider the clinical and cost effectiveness of Evusheld in order to assess its suitability for prescription in the National Health Service. The outcome of NICE’s evaluation on the use of Evusheld as a pre-exposure prophylactic treatment against COVID-19 is due in April 2023. If NICE recommends its use is clinically and cost effective, the NHS will make Evusheld available as appropriate.

Does this answer the above question?

Yes0 people think so

No5 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.